ProQR Therapeutics N.V. (PRQR)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Daniel Anton de Boer
|
Founder, CEO & Executive Director | 1.05M | -- | 1983 |
|
Dr. Gerard Platenburg Ph.D.
|
Co-Founder, Chief Scientific Officer & Executive Director | 644.84k | -- | 1964 |
|
Mr. Dennis Hom
|
Chief Financial Officer | -- | -- | 1975 |
|
Ms. Sheila Sponselee
|
Chief People & Operations Officer | -- | -- | 1984 |
|
Ms. Sarah Cue Kiely
|
Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
|
Dr. Cristina Lopez Lopez M.D., Ph.D.
|
Chief Medical Officer | -- | -- | 1976 |
|
Mr. Christopher Hart Ph.D.
|
Chief Data & AI Officer | -- | -- | -- |
|
Dr. Golnar Karimian
|
Head of Hepatology | -- | -- | -- |
|
Ms. Sandra van der Kolk
|
Junior Financial Controller | -- | -- | -- |
ProQR Therapeutics N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 186
Description
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Corporate Governance
Upcoming Events
November 9, 2026 at 1:30 PM UTC
ProQR Therapeutics N.V. Earnings Date
